WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be ...

A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...

GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...